Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Ruberg

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Therapeutic Innovation & Regulatory Science|December 21, 2022
Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical TrialsYongming Qu, Robin D White, Stephen J Ruberg
Therapeutic Innovation & Regulatory Science|July 17, 2025
Estimand Endpoints for Longitudinal Measures of Continuous Disease Progression with an Alzheimer's Disease ExampleHaoyan Hu, Miroslaw Brys, Stephen J Ruberg, et al.
Statistics in Medicine|August 5, 2011
Subgroup identification from randomized clinical trial dataJared C Foster, Jeremy M G Taylor, Stephen J Ruberg
Journal of Biopharmaceutical Statistics|January 22, 2013
Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison modelsHaoda Fu, Karen L Price, Mary E Nilsson, et al.
Biometrics|September 14, 2017
Efficiency of two sample tests via the restricted mean survival time for analyzing event time observationsLu Tian, Haoda Fu, Stephen J Ruberg, et al.
Nature Reviews. Drug Discovery|August 2, 2014
Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivityStacy R Lindborg, Charles C Persinger, Andreas Sashegyi, et al.
The Journal of Pain|July 19, 2011
Early improvement in pain predicts pain response at endpoint in patients with fibromyalgiaFujun Wang, Stephen J Ruberg, Paula J Gaynor, et al.
Clinical Pediatrics|June 5, 2010
Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patientsStan L Block, David Williams, Craig L Donnelly, et al.
Nature Reviews. Drug Discovery|February 15, 2023
Application of Bayesian approaches in drug development: starting a virtuous cycleStephen J Ruberg, Francois Beckers, Rob Hemmings, et al.
BMC Psychiatry|February 11, 2011
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophreniaStephen J Ruberg, Lei Chen, Virginia Stauffer, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Therapeutic Innovation & Regulatory Science|December 21, 2022
Accurate Collection of Reasons for Treatment Discontinuation to Better Define Estimands in Clinical TrialsYongming Qu, Robin D White, Stephen J Ruberg
Therapeutic Innovation & Regulatory Science|July 17, 2025
Estimand Endpoints for Longitudinal Measures of Continuous Disease Progression with an Alzheimer's Disease ExampleHaoyan Hu, Miroslaw Brys, Stephen J Ruberg, et al.
Statistics in Medicine|August 5, 2011
Subgroup identification from randomized clinical trial dataJared C Foster, Jeremy M G Taylor, Stephen J Ruberg
Journal of Biopharmaceutical Statistics|January 22, 2013
Identifying potential adverse events dose-response relationships via Bayesian indirect and mixed treatment comparison modelsHaoda Fu, Karen L Price, Mary E Nilsson, et al.
Biometrics|September 14, 2017
Efficiency of two sample tests via the restricted mean survival time for analyzing event time observationsLu Tian, Haoda Fu, Stephen J Ruberg, et al.
Nature Reviews. Drug Discovery|August 2, 2014
Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivityStacy R Lindborg, Charles C Persinger, Andreas Sashegyi, et al.
The Journal of Pain|July 19, 2011
Early improvement in pain predicts pain response at endpoint in patients with fibromyalgiaFujun Wang, Stephen J Ruberg, Paula J Gaynor, et al.
Clinical Pediatrics|June 5, 2010
Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patientsStan L Block, David Williams, Craig L Donnelly, et al.
Nature Reviews. Drug Discovery|February 15, 2023
Application of Bayesian approaches in drug development: starting a virtuous cycleStephen J Ruberg, Francois Beckers, Rob Hemmings, et al.
BMC Psychiatry|February 11, 2011
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophreniaStephen J Ruberg, Lei Chen, Virginia Stauffer, et al.
Pageof 2